The IND and the Thirty Day Clock

Part of Regulatory Affairs and the Jurisdiction Map: The United States under 21 CFR.

About 5 minutes. Free, in your language, no account needed.

Why this matters

The United States framework has a feature that exists almost nowhere else, and misunderstanding it in either direction causes problems.

An investigational new drug application is submitted, and the sponsor may begin the clinical investigation thirty days later unless the Food and Drug Administration notifies the sponsor that the study is subject to a clinical hold. Approval is not issued. Permission is not granted. The absence of an objection, after a defined period, is what permits the trial to begin.

Teams coming from other jurisdictions wait for an approval letter that never arrives, losing weeks. Teams who half-remember the rule proceed on day thirty-one without checking whether a hold was imposed, which is a different and more serious error.

What the submission contains

The application is built to answer whether it is reasonably safe to proceed to humans. Its core:

The general investigational plan and the protocol for each proposed study.

Chemistry, manufacturing and control information sufficient to establish the identity, quality, purity and strength of the investigational product, including the placebo.

Pharmacology and toxicology information, the non-clinical basis for concluding it is reasonably safe to conduct the proposed investigation.

Previous human experience, where any exists, including experience outside the United States.

The Investigator's Brochure, and commitments regarding investigators, review by an institutional review board, and compliance with the regulations.

The framework distinguishes commercial applications from those held by an individual investigator conducting a study of a marketed or investigational product, and the content expectations differ.

The thirty day period, precisely

The period runs from the date the agency receives the application. During it, the agency reviews for safety, specifically whether participants would be exposed to unreasonable and significant risk.

Three things can happen.

Nothing. The period expires and the sponsor may proceed. There is no letter and no confirmation; permission is constituted by the absence of a hold.

A clinical hold. The agency notifies the sponsor that the study may not begin, or may not continue, and states the grounds. A hold may be complete or partial, and it must be addressed before the affected activity proceeds.

Contact short of a hold. The agency raises questions or comments without imposing a hold. This does not extend the thirty day period, which is a point worth being exact about: informal discussion does not pause the clock the way a formal request for information does in other systems.

Grounds for a hold

The grounds are defined and knowing them shapes how the application is written. They include exposing participants to unreasonable and significant risk, investigators who are not qualified, an Investigator's Brochure that is misleading, erroneous or materially incomplete, and insufficient information to assess the risks.

Read that list and note what it is about. Almost every ground concerns the adequacy of the information supporting the safety conclusion rather than the scientific merit of the question. An application that assembles complete documents but leaves a reviewer unable to assess a risk is exposed on exactly these grounds.

In practice

A sponsor submits and hears nothing for three weeks. The study team grows anxious and asks the regulatory lead to call the agency for reassurance.

The lead does not, and the reasoning is worth stating. Silence at day twenty-one is the expected state. There is no status to be given. A call inviting a reviewer to comment on an application still under review can produce a question that would not otherwise have been asked, and the thirty day clock is not extended by the conversation.

What the lead does instead is confirm the receipt date precisely, because the period runs from receipt rather than from sending, and a two day difference in that assumption moves the start date. She then tells the study team the exact date the period expires and the exact check to perform on that date, which is confirming that no hold has been imposed rather than confirming that permission has been granted.

The distinction is not pedantry. It determines what evidence goes in the file: a record that no hold was received, with the date the period expired, rather than an approval that does not exist.

What this looks like when it goes wrong

A sponsor counts thirty days from the date it sent the submission rather than the date the agency received it, and the two differ by three days.

The site begins screening three days before the period has actually expired. Three participants are screened during a window in which the investigation was not yet permitted to begin.

Nothing alerts anybody. No letter arrives, because no letter would have arrived either way. The error surfaces later, in a reconciliation of the receipt acknowledgment against the activation date, and by then three participants have been enrolled in a study that had not lawfully begun.

This failure is specific to a framework where permission is constituted by silence. When permission arrives as a document, its date is unambiguous. When permission is the absence of an event, the start date has to be computed, and a computed date can be computed wrongly.

Key takeaways